儿科家族高胆固醇血症:针对肠道吸收和其他治疗策略
Konstantinos Arvanitakis1,2, Elena Chatzikalil3,4, Christina Antza5
1Division of Gastroenterology and Hepatology, First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece.
Nutrients
|July 30, 2025
概括
儿童的家族性高胆固醇血症 (FH) 管理可以针对肠道. 通过以泽提米布和其他策略抑制肠道胆固醇的吸收,可以有效地降低LDL-C,特别是当他类药物不理想时.
科学领域:
- 心血管医学 心血管医学
- 胃肠病学 胃肠病学
- 遗传学 是一个遗传学.
背景情况:
- 家族性高胆固醇血症 (FH) 是一种遗传性疾病,导致儿童高LDL-C,增加心血管疾病的风险.
- 虽然肝脏受体是关键的,但胃肠道对胆固醇平衡和治疗点至关重要.
研究的目的:
- 在儿科FH中审查肠道胆固醇吸收机制.
- 检查调节这些途径的药理和食干预措施.
主要方法:
- 对肠道胆固醇吸收的临床和实验证据的审查.
- 针对NPC1L1,胆酸再吸收和胆固醇排放的治疗方法的分析.
主要成果:
- 肠道胆固醇吸收的抑制对于儿科FH是有效的,特别是以泽提米布 (NPC1L1抑制剂).
- 组合治疗 (ezetimibe/statins) 显示出更大的LDL-C降低.
- 饮食干预和胆酸分离剂提供了额外的好处.
结论:
- 了解肠道胆固醇代谢对于儿科FH治疗至关重要.
- 新兴的疗法,如微生物群向策略,对未来充满希望.
- 个性化的方法是有效的儿童FH管理的关键.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
875
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
875
Lipid Absorption
752
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
752
Carrier-Mediated Transport
549
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
549
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
267
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
267
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35


